Skip to main content
Loading research indexW

Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING

rss:www.nature.com2026-08-19Abstract screenedOpen source ↗
INVESTOR TAKEAWAY

Nature Biotechnology, Published online: 19 August 2026; doi:10.1038/s41587-026-03224-y mRNA vaccine efficacy is enhanced by delayed activation of a STING adjuvant.

ORIGINAL PAPER

Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING

WHAT WE KNOW

Nature Biotechnology, Published online: 19 August 2026; doi:10.1038/s41587-026-03224-y mRNA vaccine efficacy is enhanced by delayed activation of a STING adjuvant.

WATCH NEXT

Review the primary source, validate the main result, and establish whether any listed-company transmission is direct.

EVIDENCE

What the evidence supports so far

Research signals

mRNA-platform

oncology-readout

What remains unverified

The full methodology, effect size, and limitations still require analyst review.

Company impact remains unverified until a direct economic transmission is established.